The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Cambridge Industries Group Plans Optical Module Capacity Expansion Across Four Countries

Cambridge Industries Group（剑桥科技）, or CIG, reaffirmed plans to add at least 10 million units of annual high-speed optical module capacity by the end of 2027. The expanded capacity will be allocated across production sites in China, Malaysia, Mexico and the United States.

Vital Optics Unit Signs InP Substrate Supply Letter of Intent with Coherent

Vital Optics（光智科技）said on November 6 that its controlling subsidiary Guangdong Xianrui Technology（广东先锐科技）had signed a long-term supply letter of intent with Coherent Corp.（高意）. The proposed supply of six-inch indium phosphide substrates from 2027 to 2029 has an estimated transaction value of no less than USD 601 million.

ByteDance Considers Second Phase of Brazil Data Centre Project

ByteDance（字节跳动）is seeking a developer for a potential second phase of its data centre project at the Port of Pecém in Brazil’s Ceará state, Bloomberg reported on November 6, citing people familiar with the plans. The proposed expansion remains under discussion.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.